Last updated: 3 March 2020 at 7:02pm EST

Life Sciences Ix, L.P.Fhmls... Net Worth




The estimated Net Worth of Life Sciences Ix, L.P.Fhmls... is at least $3.86 Million dollars as of 3 March 2020. Life Fhmls owns over 550,000 units of Passage Bio Inc stock worth over $3,857,099 and over the last 5 years Life sold PASG stock worth over $0.

Life Fhmls PASG stock SEC Form 4 insiders trading

Life has made over 2 trades of the Passage Bio Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Life bought 550,000 units of PASG stock worth $9,900,000 on 3 March 2020.

The largest trade Life's ever made was buying 550,000 units of Passage Bio Inc stock on 3 March 2020 worth over $9,900,000. On average, Life trades about 500,000 units every 113 days since 2019. As of 3 March 2020 Life still owns at least 5,009,219 units of Passage Bio Inc stock.

You can see the complete history of Life Fhmls stock trades at the bottom of the page.



Insiders trading at Passage Bio Inc

Over the last 5 years, insiders at Passage Bio Inc have traded over $535,533 worth of Passage Bio Inc stock and bought 4,392,148 units worth $41,339,284 . The most active insiders traders include Liam Ratcliffe, Advisors Llc Orbi Med Capit..., and Thomas Woiwode. On average, Passage Bio Inc executives and independent directors trade stock every 37 days with the average trade being worth of $92,858. The most recent stock trade was executed by Kathleen Borthwick on 10 February 2024, trading 4,000 units of PASG stock currently worth $3,080.



What does Passage Bio Inc do?

passage bio, inc., a genetic medicines company, develops transformative therapies for rare monogenic central nervous system (cns) diseases. the company develops pbgm01, which utilizes a proprietary, aavhu68 capsid to deliver to the brain and peripheral tissues a functional glb1 gene encoding lysosomal acid beta-galactosidase (ãŸ-gal) for infantile gm1; pbft02, which utilizes an aav1 capsid to deliver to the brain a functional granulin, or grn, gene encoding progranulin for the treatment of ftd caused by a deficiency of progranulin; and pbkr03, which utilizes a proprietary, aavhu68 capsid to deliver to the brain and peripheral tissues a functional galc gene encoding the hydrolytic enzyme galactosylceramidase, for infantile krabbe disease. it has a strategic research collaboration with the trustees of the university of pennsylvania's gene therapy program; and collaboration agreement, and a development services and clinical supply agreement with catalent maryland, inc. the company was fou



What does Passage Bio Inc's logo look like?

Passage Bio Inc logo

Complete history of Life Fhmls stock trades at Mirum Pharmaceuticals Inc and Passage Bio Inc

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
3 Mar 2020 Life Sciences Ix, L.P.Fhmls...
Buy 550,000 $18.00 $9,900,000
3 Mar 2020
5,009,219
22 Jul 2019 Life Sciences Ix, L.P.Fhmls...
Buy 450,000 $15.00 $6,750,000
22 Jul 2019
3,566,912


Passage Bio Inc executives and stock owners

Passage Bio Inc executives and other stock owners filed with the SEC include: